{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:09:02Z","timestamp":1792706942614,"version":"4.5.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1136\/ijgc-2022-003703","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T06:06:46Z","timestamp":1678946806000},"page":"394-402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":117,"title":["Updates on cervical cancer prevention"],"prefix":"10.1016","volume":"33","clinical-trial-number":[{"clinical-trial-number":"nct03979014","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03848039","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03832049","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03728881","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05262010","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03898167","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03064087","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9395-0627","authenticated-orcid":false,"given":"David","family":"Viveros-Carre\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0589-2696","authenticated-orcid":false,"given":"Andreina","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0093-0438","authenticated-orcid":false,"given":"Rene","family":"Pareja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2022-003703_bb0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/rmv.1822","article-title":"Human papillomavirus molecular biology and disease association","volume":"25 Suppl 1","author":"Doorbar","year":"2015","journal-title":"Rev Med Virol"},{"key":"10.1136\/ijgc-2022-003703_bb0015","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/OLQ.0000000000001355","article-title":"Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2018","volume":"48","author":"Kreisel","year":"2021","journal-title":"Sex Transm Dis"},{"key":"10.1136\/ijgc-2022-003703_bb0020","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30 Suppl 5","author":"Forman","year":"2012","journal-title":"Vaccine"},{"key":"10.1136\/ijgc-2022-003703_bb0025","first-page":"1","article-title":"Biological agents","volume":"100(Pt B)","author":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans","year":"2012","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"key":"10.1136\/ijgc-2022-003703_bb0030","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1006\/scbi.1996.0046","article-title":"Papillomavirus-like particles and HPV vaccine development","volume":"7","author":"Schiller","year":"1996","journal-title":"Semin Cancer Biol"},{"key":"10.1136\/ijgc-2022-003703_bb0035","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/j.vaccine.2017.12.079","article-title":"Explanations for the high potency of HPV prophylactic vaccines","volume":"36","author":"Schiller","year":"2018","journal-title":"Vaccine"},{"key":"10.1136\/ijgc-2022-003703_bb0040","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1016\/j.vaccine.2017.05.069","article-title":"Human papillomavirus vaccines: WHO position paper, May 2017-recommendations","volume":"35","author":"World Health Organization","year":"2017","journal-title":"Vaccine"},{"key":"10.1136\/ijgc-2022-003703_bb0045","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.coi.2017.06.009","article-title":"No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines","volume":"47","author":"Mitchell","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1136\/ijgc-2022-003703_bb0050","doi-asserted-by":"crossref","first-page":"S367","DOI":"10.1093\/infdis\/jiaa621","article-title":"Human papillomavirus vaccines","volume":"224","author":"Markowitz","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1136\/ijgc-2022-003703_bb0055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jnci\/djz074","article-title":"Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial","volume":"112","author":"Qiao","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2022-003703_bb0060","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.4161\/hv.29532","article-title":"Sustained efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination","volume":"10","author":"Naud","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1136\/ijgc-2022-003703_bb0065","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1086\/521679","article-title":"Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine","volume":"196","author":"Giuliano","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1136\/ijgc-2022-003703_bb0070","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/infdis\/jiy545","article-title":"Long-term antibody response to human papillomavirus vaccines: up to 12 years of follow-up in the Finnish maternity cohort","volume":"219","author":"Artemchuk","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1136\/ijgc-2022-003703_bb0075","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1086\/599988","article-title":"Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials","volume":"200","author":"Schiller","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1136\/ijgc-2022-003703_bb0080","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years","volume":"5","author":"Einstein","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.1136\/ijgc-2022-003703_bb0085","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003703_bb0090","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2159-8290.CD-11-0131","article-title":"Prevention of persistent human papillomavirus infection by an HPV16\/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica","volume":"1","author":"Herrero","year":"2011","journal-title":"Cancer Discov"},{"key":"10.1136\/ijgc-2022-003703_bb0095","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2022-003703_bb0100","article-title":"Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors","volume":"5","author":"Arbyn","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/ijgc-2022-003703_bb0105","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1473-3099(21)00327-3","article-title":"Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Goldstone","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1136\/ijgc-2022-003703_bb0110","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003703_bb0115","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0140-6736(17)31821-4","article-title":"Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial","volume":"390","author":"Huh","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2022-003703_bb0120","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"key":"10.1136\/ijgc-2022-003703_bb0125","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/ijc.25940","article-title":"Impact of an HPV6\/11\/16\/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16\/18 infection","volume":"129","author":"Haupt","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1136\/ijgc-2022-003703_bb0130","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S1473-3099(16)30120-7","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"16","author":"Wheeler","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1136\/ijgc-2022-003703_bb0135","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age","volume":"105","author":"Castellsagu\u00e9","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2022-003703_bb0140","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1080\/21645515.2016.1168952","article-title":"Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States","volume":"12","author":"Gee","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1136\/ijgc-2022-003703_bb0145","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.vaccine.2018.02.034","article-title":"Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the vaccine adverse event reporting system (VAERS), 2009-2015","volume":"36","author":"Arana","year":"2018","journal-title":"Vaccine"},{"key":"10.1136\/ijgc-2022-003703_bb0150","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2022-003703_bb0155","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1016\/j.vaccine.2018.02.076","article-title":"HPV single-dose vaccination: impact potential, evidence base and further evaluation","volume":"36","author":"Stanley","year":"2018","journal-title":"Vaccine"},{"key":"10.1136\/ijgc-2022-003703_bb0160","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2016.17615","article-title":"Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women","volume":"316","author":"Iversen","year":"2016","journal-title":"JAMA"},{"key":"10.1136\/ijgc-2022-003703_bb0165","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s11427-019-9547-7","article-title":"Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women","volume":"63","author":"Hu","year":"2020","journal-title":"Sci China Life Sci"},{"key":"10.1136\/ijgc-2022-003703_bb0170","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/djx158","article-title":"Durability of protection afforded by fewer doses of the HPV16\/18 vaccine: the CVT trial","volume":"110","author":"Safaeian","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2022-003703_bb0175","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"key":"10.1136\/ijgc-2022-003703_bb0180","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(15)00414-3","article-title":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study","volume":"17","author":"Sankaranarayanan","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-003703_bb0185","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/jnci\/djaa011","article-title":"Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial","volume":"112","author":"Kreimer","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2022-003703_bb0190","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-021-05608-8","article-title":"Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE study): study protocol for a randomized controlled trial","volume":"22","author":"Barnabas","year":"2021","journal-title":"Trials"},{"key":"10.1136\/ijgc-2022-003703_bb0195","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study","volume":"398","author":"Falcaro","year":"2021","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2022-003703_bb0200","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003703_bb0205","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2018.08.033","article-title":"SPERANZA project: HPV vaccination after treatment for CIN2","volume":"151","author":"Ghelardi","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003703_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8020245","article-title":"HPV vaccination as adjuvant to conization in women with cervical intraepithelial neoplasia: a study under real-life conditions","volume":"8","author":"Del Pino","year":"2020","journal-title":"Vaccines"},{"key":"10.1136\/ijgc-2022-003703_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10020288","article-title":"Effectiveness of prophylactic human papillomavirus vaccine in the prevention of recurrence in women conized for HSIL\/CIN 2-3: the VENUS study","volume":"10","author":"Casajuana-P\u00e9rez","year":"2022","journal-title":"Vaccines"},{"key":"10.1136\/ijgc-2022-003703_bb0220","doi-asserted-by":"crossref","first-page":"6402","DOI":"10.1016\/j.vaccine.2020.07.055","article-title":"Prophylactic HPV vaccination after conization: a systematic review and meta-analysis","volume":"38","author":"Jentschke","year":"2020","journal-title":"Vaccine"},{"key":"10.1136\/ijgc-2022-003703_bb0225","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/AOG.0000000000003833","article-title":"Adjuvant human papillomavirus vaccine to reduce recurrent cervical dysplasia in unvaccinated women: a systematic review and meta-analysis","volume":"135","author":"Lichter","year":"2020","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2022-003703_bb0230","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-020-8371-z","article-title":"Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial","volume":"20","author":"Karimi-Zarchi","year":"2020","journal-title":"BMC Public Health"},{"key":"10.1136\/ijgc-2022-003703_bb0235","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00404-018-4926-y","article-title":"Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease","volume":"298","author":"Pieralli","year":"2018","journal-title":"Arch Gynecol Obstet"},{"key":"10.1136\/ijgc-2022-003703_bb0240","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/aogs.14359","article-title":"Human papillomavirus vaccination in women undergoing excisional treatment for cervical intraepithelial neoplasia and subsequent risk of recurrence: a systematic review and meta-analysis","volume":"101","author":"Eriksen","year":"2022","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1136\/ijgc-2022-003703_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2020.106335","article-title":"National implementation of HPV vaccination programs in low-resource countries: lessons, challenges, and future prospects","volume":"144","author":"Tsu","year":"2021","journal-title":"Prev Med"},{"key":"10.1136\/ijgc-2022-003703_bb0250","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jadohealth.2018.06.024","article-title":"Reasons for lack of HPV vaccine initiation in NIS-Teen over time: shifting the focus from gender and sexuality to necessity and safety","volume":"63","author":"Beavis","year":"2018","journal-title":"J Adolesc Health"},{"key":"10.1136\/ijgc-2022-003703_bb0255","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1016\/j.vaccine.2018.04.075","article-title":"Correlates of HPV vaccine initiation and provider recommendation among male adolescents, 2014 NIS-Teen","volume":"36","author":"Landis","year":"2018","journal-title":"Vaccine"},{"key":"10.1136\/ijgc-2022-003703_bb0260","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapediatrics.2015.0310","article-title":"Practice- and community-based interventions to increase human papillomavirus vaccine coverage: a systematic review","volume":"169","author":"Niccolai","year":"2015","journal-title":"JAMA Pediatr"},{"key":"10.1136\/ijgc-2022-003703_bb0265","article-title":"Effectiveness and costs of an implemented primary HPV cervical screening programme in Sweden - a population based cohort study","volume":"25","author":"Bergengren","year":"2022","journal-title":"Prev Med Rep"},{"key":"10.1136\/ijgc-2022-003703_bb0270","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMsr2030640","article-title":"The IARC perspective on cervical cancer screening","volume":"385","author":"Bouvard","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003703_bb0275","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/ijc.25553","article-title":"Trends in cervical cancer in the Netherlands until 2007: has the bottom been reached?","volume":"128","author":"De Kok","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1136\/ijgc-2022-003703_bb0280","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/bjc.2014.362","article-title":"50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence","volume":"111","author":"Vaccarella","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2022-003703_bb0285","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/j.1471-0528.2008.01865.x","article-title":"A randomised comparison of SurePath liquid-based cytology and conventional smear cytology in a colposcopy clinic setting","volume":"115","author":"Sykes","year":"2008","journal-title":"BJOG"},{"key":"10.1136\/ijgc-2022-003703_bb0290","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1002\/ijc.27955","article-title":"A randomized trial comparing conventional cytology to liquid-based cytology and computer assistance","volume":"132","author":"Klug","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1136\/ijgc-2022-003703_bb0295","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ypmed.2018.12.021","article-title":"HPV-based cervical screening: rationale, expectations and future perspectives of the new Dutch screening programme","volume":"119","author":"Polman","year":"2019","journal-title":"Prev Med"},{"key":"10.1136\/ijgc-2022-003703_bb0300","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1188\/16.CJON.79-83","article-title":"Cervical cancer screening in developing countries: using visual inspection methods","volume":"20","author":"Lee","year":"2016","journal-title":"Clin J Oncol Nurs"},{"key":"10.1136\/ijgc-2022-003703_bb0305","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.a1754","article-title":"Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study","volume":"337","author":"Dillner","year":"2008","journal-title":"BMJ"},{"key":"10.1136\/ijgc-2022-003703_bb0310","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2022-003703_bb0315","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju153","article-title":"Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test","volume":"106","author":"Gage","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2022-003703_bb0320","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ygyno.2014.11.076","article-title":"Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test","volume":"136","author":"Wright","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003703_bb0325","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/LGT.0000000000000103","article-title":"Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance","volume":"19","author":"Huh","year":"2015","journal-title":"J Low Genit Tract Dis"},{"key":"10.1136\/ijgc-2022-003703_bb0330","doi-asserted-by":"crossref","first-page":"E613","DOI":"10.1503\/cmaj.211568","article-title":"Shifting from cytology to HPV testing for cervical cancer screening in Canada","volume":"194","author":"Delpero","year":"2022","journal-title":"CMAJ"},{"key":"10.1136\/ijgc-2022-003703_bb0335","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors","volume":"24","author":"Perkins","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"10.1136\/ijgc-2022-003703_bb0340","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/jog.14168","article-title":"Screening and management of preinvasive lesions of the cervix: good clinical practice recommendations from the Federation of Obstetrics and Gynaecologic Societies of India (FOGSI)","volume":"46","author":"Bhatla","year":"2020","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1136\/ijgc-2022-003703_bb0345","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-035796","article-title":"Multicentric study of cervical cancer screening with human papillomavirus testing and assessment of triage methods in Latin America: the ESTAMPA screening study protocol","volume":"10","author":"Almonte","year":"2020","journal-title":"BMJ Open"},{"key":"10.1136\/ijgc-2022-003703_bb0350","first-page":"S30","article-title":"Training for cervical cancer prevention programs in low-resource settings: focus on visual inspection with acetic acid and cryotherapy","volume":"89 Suppl 2","author":"Blumenthal","year":"2005","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1136\/ijgc-2022-003703_bb0355","author":"Sankaranarayanan","year":"2003"},{"key":"10.1136\/ijgc-2022-003703_bb0360","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ijgo.2010.01.019","article-title":"Cervical cancer screening with naked-eye visual inspection in Colombia","volume":"109","author":"Murillo","year":"2010","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1136\/ijgc-2022-003703_bb0365","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0140-6736(07)61195-7","article-title":"Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial","volume":"370","author":"Sankaranarayanan","year":"2007","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2022-003703_bb0370","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijgo.2010.10.012","article-title":"Accuracy of visual inspection with acetic acid for cervical cancer screening","volume":"113","author":"Sauvaget","year":"2011","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1136\/ijgc-2022-003703_bb0375","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/ijc.20190","article-title":"Accuracy of visual screening for cervical neoplasia: results from an IARC multicentre study in India and Africa","volume":"110","author":"Sankaranarayanan","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1136\/ijgc-2022-003703_bb0380","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/ijc.21972","article-title":"Visual inspection as a cervical cancer screening method in a primary health care setting in Africa","volume":"119","author":"Sangwa-Lugoma","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1136\/ijgc-2022-003703_bb0385","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s00404-011-2203-4","article-title":"Analysis of the effectiveness of visual inspection with acetic acid\/Lugol's iodine in one-time and annual follow-up screening in rural China","volume":"285","author":"Li","year":"2012","journal-title":"Arch Gynecol Obstet"},{"key":"10.1136\/ijgc-2022-003703_bb0390","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bpobgyn.2020.02.008","article-title":"Primary HPV screening for cervical cancer","volume":"65","author":"Bhatla","year":"2020","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1136\/ijgc-2022-003703_bb0395","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.cmi.2020.03.033","article-title":"Commercially available molecular tests for human papillomaviruses: a global overview","volume":"26","author":"Poljak","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1136\/ijgc-2022-003703_bb0400","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.24010","article-title":"Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older","volume":"124","author":"Meijer","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1136\/ijgc-2022-003703_bb0405","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.jcv.2015.09.014","article-title":"VALGENT: a protocol for clinical validation of human papillomavirus assays","volume":"76 Suppl 1","author":"Arbyn","year":"2016","journal-title":"J Clin Virol"},{"key":"10.1136\/ijgc-2022-003703_bb0410","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.cmi.2021.04.031","article-title":"2020 list of human papillomavirus assays suitable for primary cervical cancer screening","volume":"27","author":"Arbyn","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1136\/ijgc-2022-003703_bb0415","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1470-2045(22)00294-7","article-title":"Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis","volume":"23","author":"Arbyn","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-003703_bb0420","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-022-03383-x","article-title":"Clinical validation of full HR-HPV genotyping HPV Selfy assay according to the international guidelines for HPV test requirements for cervical cancer screening on clinician-collected and self-collected samples","volume":"20","author":"Avian","year":"2022","journal-title":"J Transl Med"},{"key":"10.1136\/ijgc-2022-003703_bb0425","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41416-020-0920-9","article-title":"Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC)","volume":"123","author":"Kyrgiou","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2022-003703_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100293","article-title":"A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs","volume":"22","author":"Demarco","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1136\/ijgc-2022-003703_bb0435","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamainternmed.2019.0306","article-title":"Clinical evaluation of human papillomavirus screening with p16\/Ki-67 dual stain triage in a large organized cervical cancer screening program","volume":"179","author":"Wentzensen","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1136\/ijgc-2022-003703_bb0440","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1093\/cid\/ciz677","article-title":"Methylation in predicting progression of untreated high-grade cervical intraepithelial neoplasia","volume":"70","author":"Louvanto","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1136\/ijgc-2022-003703_bb0445","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ijc.31261","article-title":"Eurogin roadmap 2017: triage strategies for the management of HPV-positive women in cervical screening programs","volume":"143","author":"Cuschieri","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1136\/ijgc-2022-003703_bb0450","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-12-551","article-title":"Development of a multiplex methylation-specific PCR as candidate triage test for women with an HPV-positive cervical scrape","volume":"12","author":"Snellenberg","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1136\/ijgc-2022-003703_bb0455","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2022-003703_bb0460","doi-asserted-by":"crossref","DOI":"10.1186\/s12905-021-01511-1","article-title":"Prevalence of vaccine and non-vaccine human papillomavirus types among women in Accra and Kumasi, Ghana: a cross-sectional study","volume":"21","author":"Debrah","year":"2021","journal-title":"BMC Womens Health"},{"key":"10.1136\/ijgc-2022-003703_bb0465","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.14020","article-title":"Test performance of cervical cytology among adults with vs without human papillomavirus vaccination","volume":"5","author":"Teoh","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1136\/ijgc-2022-003703_bb0470","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw216","article-title":"Optimal cervical cancer screening in women vaccinated against human papillomavirus","volume":"109","author":"Kim","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2022-003703_bb0475","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-020-04790-5","article-title":"Mailed self-sample HPV testing kits to improve cervical cancer screening in a safety net health system: protocol for a hybrid effectiveness-implementation randomized controlled trial","volume":"21","author":"Montealegre","year":"2020","journal-title":"Trials"},{"key":"10.1136\/ijgc-2022-003703_bb0480","article-title":"Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses","volume":"363","author":"Arbyn","year":"2018","journal-title":"BMJ"},{"key":"10.1136\/ijgc-2022-003703_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2021.106900","article-title":"Worldwide use of HPV self-sampling for cervical cancer screening","volume":"154","author":"Serrano","year":"2022","journal-title":"Prev Med"},{"key":"10.1136\/ijgc-2022-003703_bb0490","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S1470-2045(13)70570-9","article-title":"Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis","volume":"15","author":"Arbyn","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-003703_bb0495","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","article-title":"Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis","volume":"8","author":"Arbyn","year":"2020","journal-title":"Lancet Glob Health"},{"key":"10.1136\/ijgc-2022-003703_bb0500","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2022.33.e4","article-title":"Accuracy of human papillomavirus tests on self-collected urine versus clinician-collected samples for the detection of cervical precancer: a systematic review and meta-analysis","volume":"33","author":"Cho","year":"2022","journal-title":"J Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003703_bb0505","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jcv.2018.08.006","article-title":"VALHUDES: a protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples","volume":"107","author":"Arbyn","year":"2018","journal-title":"J Clin Virol"},{"key":"10.1136\/ijgc-2022-003703_bb0510","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ygyno.2021.06.010","article-title":"Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol","volume":"162","author":"Van Keer","year":"2021","journal-title":"Gynecol Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24009447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24009447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2022-003703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:40:39Z","timestamp":1753224039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24009447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1048891X24009447"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2022-003703","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates on cervical cancer prevention","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2022-003703","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}